Dec 8, 2011 | BioSpace
Metabolex, Inc. Announces Positive Results From its Clinical Study of ...
A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid .
Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that its arhalofenate program has been recognized in Windhover's "Top 10 most interesting cardiovascular/metabolic diseases projects to watch." Arhalofenate is a potential ... (more)
Metabolex, Inc. to Present Data on Arhalofenate, a Potential Novel...
Metabolex, Inc. to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, today announced that it will be presenting ... (more)